Larotrectinib Will Change TRK Fusion Treatment | Bring New 1st-in-Class Drugs to Patients

Scott Z. Fields, MD, Bayer Pharmaceuticals explains Larotrectinib Will Change TRK Fusion Treatment | Bring New 1st-in-Class Drugs to Patients at ASCO 2018 Author: Annual-Meeting Added: 06/21/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts